General
Preferred name
TRANEXAMIC ACID
Synonyms
Tranexamic ()
Amstat ()
Tranexamsaeure ()
tranexamic acid, Xenoport ()
Transamin ()
CL-65336 ()
Espercil ()
Acido tranexamico ()
Menstralite ()
Acide tranexamique ()
Lysteda ()
Femstrual ()
Cyklokapron ()
Amcha ()
NSC-291305 ()
Cyclo-f ()
CL 65336 ()
Trans AMCHA ()
TRANS-AMCHA ()
Haematrix ()
cyclocapron ()
LB-1148 ()
RP-18429 ()
Rikavarin ()
Exacyl ()
CL65336 ()
LB1148 ()
Cyclokapron ()
Cyklo-f Heavy Period Relief ()
Tranexamic Acid-13C2,15N ()
P&D ID
PD001423
CAS
1197-18-8
1292837-95-6
Tags
available
drug
Approved by
FDA
First approval
1986
Drug Status
approved
Max Phase
4.0
Drug indication
hemorrhage
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
This ligand is represented on PubChem without specified stereochemistry by CID 5526.
(GtoPdb)
PRICE
29
DESCRIPTION
Tranexamic acid is an antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin.
(Enamine Bioactive Compounds)
DESCRIPTION
Tranexamic acid (Amstat) is an Antifibrinolytic Agent. The physiologic effect of tranexamic acid is by means of Decreased Fibrinolysis.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
26
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
157.11
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
0
cLogP
0.84
TPSA
63.32
Fraction CSP3
0.88
Chiral centers
0.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Plasminogen inhibitor
Tissue-Type Plasminogen Activator (t-PA) Inhibitors
antifibrinolytic, plasminogen activator inhibitor
Target
Plasminogen
PLG
Member status
member
Indication
hemophilia
Source data
